Preclinical Strategy & Execution,
Built for What Comes Next
Fractionalized preclinical support from GLSA helps companies move confidently from discovery toward IND readiness without the need to build a full internal team.
GLSA connects life sciences organizations with pre-vetted preclinical partners and resources to advance programs efficiently from discovery through IND-enabling milestones. Through our global network, we provide the right expertise, services, and infrastructure, exactly when you need it, without the burden of building it all in-house.
Global Network • Fractionalized Support • Preclinical-Focused Expertise
Whether you need strategic guidance, specialized execution, or trusted service providers, GLSA helps you de-risk early development, control costs, and build a strong foundation for clinical success.
Mentorship & Scientific Leadership • Developing talent. Elevating standards.
A committed mentor and scientific leader, he fosters high-performing teams across preclinical and clinical environments. By cultivating technical excellence and strategic thinking, he empowers teams to deliver rigorous bioanalytical results and operational success.
Build a Strong Preclinical Foundation
Leverage GLSA’s Preclinical Network partners and resources to move your program forward with clarity, confidence, and the right support at every stage.
Andrew Macintyre, MD PhD
Fractional CMO & Strategic Bioanalytical & Translational Research Officer
Fractionalized and On Demand Support
End-to-End Preclinical Strategy & Development Services
Bioanalytical &Clinical Leadership
Experience you can move with confidence.
With experience advancing more than 30 drug development programs into late-stage clinical trials, Andy brings strategic clarity and operational precision to complex therapeutic landscapes. His leadership in global bioanalytical operations ensures that innovative treatments move efficiently.
-
Global bioanalytical operations leadership
-
Therapeutic landscape strategy and program advancement
-
Seamless progression from early to late-stage clinical trials
Immuno-Oncology & toxicology
Advancing immune science with purpose.
A recognized leader in Immuno-Oncology and Immunotoxicology, he has pioneered advanced methodologies to evaluate immune responses in clinical development. His work has enabled more precise, data-driven decision-making in complex trials strengthening safety assessments.
-
Advanced immune response assay development
-
Clinical immunotoxicology strategy and safety evaluation
-
Precision-driven approaches to complex therapeutic programs
Executive Strategy & Leadership
Guiding innovation through pathways.
With extensive experience in global regulatory strategy, he has authored and led the submission of numerous 510(k), IND, and BLA applications, securing approvals from the U.S. Food and Drug Administration and European regulatory authorities.
-
IND, BLA, and 510(k) submission strategy and execution
-
U.S. and European regulatory navigation
-
Strategic CRO and pharmaceutical partnership leadership
Preclinical Strategy
Strategy to move with confidence.
GLSA provides fractionalized preclinical leadership to align science, strategy, and execution.
-
IND-enabling strategies and preclinical planning
-
Asset prioritization and risk mitigation planning
-
Alignment with regulatory and clinical objectives
Fractionalized Services
The right partners for the right studies.
Connect with trusted fractionalized Advisors, Consultants, and specialized vendors.
-
In vivo, in vitro, and ex vivo study support
-
Pharmacology, toxicology, and safety assessment partners
-
Vendor selection based on expertise, fit, and program needs
Translational & Biomarkers
Bridge discovery and clinical strategy
GLSA helps integrate translational science to strengthen clinical relevance and decision-making.
-
Biomarker strategy and assay development
-
Translational study design and data integration
-
Partner coordination for sample analysis and interpretation
Regulatory & IND-Support
Prepare early with the end in mind
Ensure preclinical work supports regulatory success and future clinical trials.
-
IND-enabling study planning and documentation support
-
Regulatory strategy alignment and readiness assessments
-
Coordination with regulatory consultants and experts
Data & Scientific Reporting
Turn preclinical data into insights
GLSA ensures preclinical results are organized, interpretable, and decision ready.
-
Study data review and quality oversight
-
Integrated reporting across multiple vendors
-
Scientific summaries to support investors and partners
Licensing & Co-Development
Advance strategic Partnerships
Support licensing & co-development by positioning assets, aligning partners, and enabling investors.
-
Identify, evaluate, and engage licensing partners
-
Connect and support investor discussions
-
Align preclinical milestones for partnering and valuation
Sign up to receive notifications and alerts for GLSA Investor Connections, including emerging opportunities and curated introductions.
Sign up to receive notifications and alerts for upcoming in-person and virtual
GLSA / FOCM Networking Events to network with industry professionals.
Life Science Professionals can sign up to receive alerts for GLSA Accelerated Partnering. Curated, time-efficient spotlights to potential partners.
